<DOC>
	<DOCNO>NCT02717949</DOCNO>
	<brief_summary>There still remain question hepatitis C eradication oral therapy lead regression cure low grade lymphoma . Thus , hypothesis study oral HCV therapy lead high rate hepatitis C eradication correlate reduction size extent low-grade lymphoma . The hypothesis study subject hepatitis C , regardless genotype , low grade lymphoma , treat hepatitis C without pegylated interferon regression low grade non-Hodgkin 's lymphoma . In pilot study evaluate effect Sofosbuvir/ledipasvir sofosbuvir/ribavirin base antiviral therapy course subset HCV-related low grade B cell non-Hodgkin 's lymphoma Primary Objective This study ass safety , measure adverse event , subject receive hepatitis C treatment . Secondary Objective The secondary objective study ass rate overall response B cell non-Hodgkin 's lymphoma define either partial response complete response accord revise international work group criterion non-Hodgkin lymphoma . Primary Endpoint Safety tolerability sofosbuvir/ledipasvir sofosbuvir/ribavirin subject B-cell non-Hodgkin 's lymphoma assess number adverse event serious adverse event . In addition , study assess number subject stop treatment due adverse event serious adverse event . The study also examine number subject treatment lymphoma give due clinical progression . Secondary Endpoints The secondary endpoint ( ) study ( 1 ) Assess rate overall response B-cell Non-Hodgkin 's lymphoma define either partial response complete response accord revise international work group criterion non-Hodgkin lymphoma . ( 2 ) Determine rate sustain viral response subject low-grade lymphoma .</brief_summary>
	<brief_title>Oral Hepatitis C Treatment Indolent Lymphoma ( OPTImaL ) Study</brief_title>
	<detailed_description>Methods Study Design The study plan enroll approximately 21 subject next 6-12 month study . Subjects low grade lymphoma confirm diagnosis hepatitis C viral load &gt; 1000 include study . Subjects may treatment naïve experience hepatitis C therapy , however subject must treatment naïve non-Hodgkin 's lymphoma treatment include study . All subject undergo stag study time study screen include whole body scan bone marrow biopsy . In prior bone marrow biopsy , bone marrow involvement biopsy &lt; 3 month screen , additional biopsy need . If bone marrow biopsy show bone marrow involvement , repeat bone marrow biopsy need screening . If complete data available prior biopsy , repeat bone marrow biopsy need do . In addition , patient stag liver disease serologic marker liver inflammation , aspartate aminotransferase ( AST ) platelet ratio ( APRI ) FibroTest® ( Fibro Sure® ) FibroScan® . If method inconclusive , liver biopsy may obtain determine patient cirrhosis . Patients treat regardless stage fibrosis . The rationale examine cirrhosis patient may respond well require surveillance hepatocellular cancer every 6 month . Additionally , hepatitis C viral load genotype determine prior initiation hepatitis C treatment . Setting : This multi- center study conduct University Texas Southwestern Medical Center , Cornell Medical Center , Memorial Sloan Kettering Cancer Center . Each site would expect enroll 7 subject 6-12 month . Treatment Genotype 1 : Treatment Naïve , without cirrhosis : sofosbuvir/ledipasvir one pill day 12 week . Treatment experience , cirrhosis : sofosbuvir/ledipasvir one pill day weight-based ribavirin 12 week . Weight-based ribavirin refers use 1200 mg ribavirin divide dos ≥75 kg 1000 mg divide dose &lt; 75kg . Treatment experienced cirrhosis : sofosbuvir/ledipasvir one pill day 24 week . This option subject unable take ribavirin . Genotype 2 : Treatment naïve experience without cirrhosis : sofosbuvir 400mg daily ribavirin 1000/1200 mg weight-based dosing divide dose twice day 12 weeks.Treatment naïve experience cirrhosis : sofosbuvir 400 mg weight-based ribavirin 16 week Genotype 3 : Treatment naïve , non-cirrhotic : sofosbuvir/ledipasvir fix dose combination combine weight-based ribavirin 12 week treatment naïve cirrhosis : sofosbuvir 400 mg daily weight-based ribavirin 24 week . Treatment experience cirrhosis exclude best treatment population would require pegylated interferon . Genotype 4 : Treatment naïve without cirrhosis treatment experience without cirrhosis : sofosbuvir/Ledipasvir fix dose combination 12 week . Treatment experienced cirrhosis : sofosbuvir/ledipasvir 24 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>1 . Willing able provide write informed consent . 2 . Male female &gt; 18 year age 3 . Serum HCV RNA level &gt; 1,000 IU per milliliter high 4 . HCV treatment experience naïve . HCV treatment naïve : No prior exposure Interferon , ribavirin , approve experimental HCVspecific directly act antiviral HCV TreatmentExperienced : Virologic failure treatment Pegylated interferon + ribavirin , Nonstructural 3/4a ( NS3/4A ) protease inhibitor plus pegylated interferon + ribavirin , regimen sofosbuvir±ribavirin± pegylated interferon regimen . 5 . Chronic Hepatitis C base judgment investigator 6 . HCV genotype 1 , 2 , 3 , 4 7 . If patient determine cirrhotic ( base criterion outline earlier ) , patient must ultrasound do within 6 month prior enrollment evidence hepatocellular carcinoma . 8 . Indolent NonHodgkin 's lymphoma , may include follow : Nodal Marginal zone lymphoma Extranodal marginal zone lymphoma ( MALT ) Splenic marginal zone lymphoma Follicular lymphoma Grade 13a low tumor burden* , FLIPI 2 risk category either low ( i.e . risk factor ) intermediate ( 12 risk factor ) , B symptom . B symptom define : Fever ( i.e. , temperature &gt; 38°C [ &gt; 100.4°F ] ) 3 consecutive day Weight loss exceed 10 % body weight 6 month Drenching night sweat Lymphoplasmacytic lymphoma 9 . No prior chemotherapy Low tumor burden define normal lactate dehydrogenase , large nodal extranodal mass le 7 cm , three nodal sit contain node diameter great 3 cm , clinically significant serous effusion detectable physical examination positron emission tomography ( PET ) /CT scan , spleen enlargement 16 cm CT without evidence portal hypertension . 10 . Karnofsky performance status &gt; 70 % 11 . Creatinine clearance ≥60 mL/min , calculate CockcroftGault equation 12 . If patient need ribavirin regimen follow inclusion : Hg &gt; 12 g/dL male Hg &gt; 11 g/dL female 13 . All woman childbearing potential take ribavirin need negative urine pregnancy test . 1 . Life expectancy &lt; 6 month 2 . Any HCV treatment use pegylated interferon 3 . HCV genotype 3 Treatment experience cirrhosis 4 . Coinfection hepatitis B 5 . Prior chemotherapy lymphoma 6 . Lymphomas histologies one list section 3.3 7 . Follicular lymphoma large cell transformation 8 . Decompensated liver disease pegylated interferon contraindicate . 9 . Female pregnant breast feed HCV treatment require use ribavirin . 10 . Solid organ transplant 11 . Any interferon containing agent within 8 week prior screen prior exposure HCVspecific antiviral agent ( ) , NS3/ 4A protease inhibitor sofosbuvir 12 . Known hypersensitivity ledipasvir , sofosbuvir , formulation excipients . 13 . On prohibited medication stop duration HCV treatment . 14 . Female subject pregnant breastfeeding 15 . HIVinfection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>low-grade lymphoma</keyword>
</DOC>